Your browser doesn't support javascript.
loading
A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma.
Ko, Andrew H; Bekaii-Saab, Tanios; Van Ziffle, Jessica; Mirzoeva, Olga M; Joseph, Nancy M; Talasaz, AmirAli; Kuhn, Peter; Tempero, Margaret A; Collisson, Eric A; Kelley, R Kate; Venook, Alan P; Dito, Elizabeth; Ong, Anna; Ziyeh, Sharvina; Courtin, Ryan; Linetskaya, Regina; Tahiri, Sanaa; Korn, W Michael.
Afiliación
  • Ko AH; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California. andrewko@medicine.ucsf.edu.
  • Bekaii-Saab T; Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
  • Van Ziffle J; Department of Pathology, University of California San Francisco, San Francisco, California.
  • Mirzoeva OM; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.
  • Joseph NM; Department of Pathology, University of California San Francisco, San Francisco, California.
  • Talasaz A; Guardant Health, Inc., Redwood City, California.
  • Kuhn P; University of Southern California, Los Angeles, California.
  • Tempero MA; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.
  • Collisson EA; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.
  • Kelley RK; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.
  • Venook AP; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.
  • Dito E; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.
  • Ong A; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.
  • Ziyeh S; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.
  • Courtin R; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.
  • Linetskaya R; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.
  • Tahiri S; Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
  • Korn WM; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.
Clin Cancer Res ; 22(1): 61-8, 2016 Jan 01.
Article en En | MEDLINE | ID: mdl-26251290
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas / Adenocarcinoma / Protocolos de Quimioterapia Combinada Antineoplásica / Terapia Molecular Dirigida Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2016 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas / Adenocarcinoma / Protocolos de Quimioterapia Combinada Antineoplásica / Terapia Molecular Dirigida Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2016 Tipo del documento: Article